Literature DB >> 12458032

Mast cells: new targets for multiple sclerosis therapy?

Jacques P Zappulla1, Michel Arock, Lennart T Mars, Roland S Liblau.   

Abstract

Growing evidence suggests that mast cells (MCs) play a crucial role in the inflammatory process and the subsequent demyelination observed in patients suffering from multiple sclerosis (MS). Although no consensus exists on the role of mast cells in multiple sclerosis, recent results from animal models clearly indicate that these cells act at multiple levels to influence both the induction and the severity of disease. In addition to changing our views on the pathophysiology of multiple sclerosis, the concept that mast cells are critical for the outcome of the disease could have an important impact on the development of new therapeutic approaches.

Entities:  

Mesh:

Year:  2002        PMID: 12458032     DOI: 10.1016/s0165-5728(02)00250-3

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  16 in total

Review 1.  Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis.

Authors:  David C Mohr; Stacey L Hart; Laura Julian; Darcy Cox; Daniel Pelletier
Journal:  BMJ       Date:  2004-03-19

Review 2.  Mast cells and inflammation.

Authors:  Theoharis C Theoharides; Konstantinos-Dionysios Alysandratos; Asimenia Angelidou; Danae-Anastasia Delivanis; Nikolaos Sismanopoulos; Bodi Zhang; Shahrzad Asadi; Magdalini Vasiadi; Zuyi Weng; Alexandra Miniati; Dimitrios Kalogeromitros
Journal:  Biochim Biophys Acta       Date:  2010-12-23

3.  Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells.

Authors:  D Kempuraj; M Tagen; B P Iliopoulou; A Clemons; M Vasiadi; W Boucher; M House; A Wolfberg; T C Theoharides
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

4.  Neuroinflammation Induces Neurodegeneration.

Authors:  D Kempuraj; R Thangavel; P A Natteru; G P Selvakumar; D Saeed; H Zahoor; S Zaheer; S S Iyer; A Zaheer
Journal:  J Neurol Neurosurg Spine       Date:  2016-11-18

5.  Massive apoptosis in lymphoid organs in animal models for primary and secondary progressive multiple sclerosis.

Authors:  Ikuo Tsunoda; Jane E Libbey; Li-Qing Kuang; Emily Jane Terry; Robert S Fujinami
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

Review 6.  Role of Mast Cells in the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.

Authors:  Daniel Elieh-Ali-Komi; Yonghao Cao
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

7.  Lipocalin-2 protein deficiency ameliorates experimental autoimmune encephalomyelitis: the pathogenic role of lipocalin-2 in the central nervous system and peripheral lymphoid tissues.

Authors:  Youngpyo Nam; Jong-Heon Kim; Minchul Seo; Jae-Hong Kim; Myungwon Jin; Sangmin Jeon; Jung-wan Seo; Won-Ha Lee; So Jin Bing; Youngheun Jee; Won Kee Lee; Dong Ho Park; Hyun Kook; Kyoungho Suk
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

8.  Comparison of serum apolipoprotein A-I between Chinese multiple sclerosis and other related autoimmune disease.

Authors:  Bin Zhang; ShuXiang Pu; BinMei Li; JianRui Ying; Xing Wang Song; Cong Gao
Journal:  Lipids Health Dis       Date:  2010-03-29       Impact factor: 3.876

Review 9.  Physiological and pathophysiological functions of intestinal mast cells.

Authors:  Stephan C Bischoff
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

10.  Luteolin as a therapeutic option for multiple sclerosis.

Authors:  Theoharis C Theoharides
Journal:  J Neuroinflammation       Date:  2009-10-13       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.